Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Multidrug resistance protein 1 (ABCB1), also widely known as P-glycoprotein 1 (P-gp), is a well-characterized ATP-dependent efflux transporter belonging to the ATP-binding cassette (ABC) transporter superfamily. It is primarily expressed in apical membranes of epithelial cells in barrier and excretory organs, such as the blood-brain barrier, small intestine, liver, and kidneys, where it plays a crucial protective role by pumping xenobiotics and toxic substances out of cells and back into the bloodstream or excretory pathways. In oncology, the overexpression of ABCB1 in cancer cells is a major mechanism of multidrug resistance, as it actively extrudes a wide range of structurally diverse chemotherapeutic agents, including taxanes, anthracyclines, and vinca alkaloids, thereby reducing their therapeutic efficacy. Consequently, ABCB1 has been a major target for the development of reversal agents (inhibitors) to restore chemosensitivity, though clinical success has been limited by systemic toxicities and complex drug-drug interactions. Additionally, genetic variations or mutations in the ABCB1 gene can significantly alter drug pharmacokinetics, leading to severe drug sensitivities and toxicities, particularly in the central nervous system.
Drugs targeting ABCB1 typically act as inhibitors or modulators to block the efflux of chemotherapeutic agents, thereby reversing multidrug resistance and increasing intracellular drug accumulation. Alternatively, many drugs are substrates of ABCB1, and their pharmacokinetics, systemic clearance, and tissue distribution (such as brain penetration) are determined by their active extrusion by this transporter.
15 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multidrug resistance protein 1 (ABCB1).